Open access · CC-BY
via OpenAlex
Impact of aging on treatment considerations for multiple sclerosis patients
Gabrielle Macaron, Catherine Larochelle, Nathalie Arbour, Manon Galmard, Marc Girard, Alexandre Prat, Pierre Duquette
Frontiers in Neurology · 2023 · ▲ 66 citations
Abstract
With a rapidly aging global population and improvement of outcomes with newer multiple sclerosis (MS)-specific disease-modifying therapies (DMTs), the epidemiology of MS has shifted to an older than previously described population, with a peak prevalence of the disease seen in the 55-65 years age group. Changes in the pathophysiology of MS appear to be age-dependent. Several studies have identified a consistent phase of disability worsening around the fifth decade of life. The latter appears to be independent of prior disease duration and inflammatory activity and concomitant to pathological changes from acute focal active demyelination to chronic smoldering plaques, slow-expanding lesions, and compartmentalized inflammation within the central nervous system (CNS). On the other hand, decreased CNS tissue reserve and poorer remyelinating capacity with aging lead to loss of relapse recovery potential. Aging with MS may imply longer exposure to DMTs, although treatment efficacy in patients >55 years has not been evaluated in pivotal randomized controlled trials and appears to decrease with age. Older individuals are more prone to adverse effects of DMTs, an important aspect of treatment individualization. Aging with MS also implies a higher global burden of comorbid illnesses that contribute to overall impairments and represent a crucial confounder in interpreting clinical worsening. Discontinuation of DMTs after age 55, when no evidence of clinical or radiological activity is detected, is currently under the spotlight. In this review, we will discuss the impact of aging on MS pathobiology, the effect of comorbidities and other confounders on clinical worsening, and focus on current therapeutic considerations in this age group.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fneur.2023.1197212
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Macaron, G., Larochelle, C., Arbour, N., Galmard, M., Girard, M., Prat, A., & Duquette, P. (2023). Impact of aging on treatment considerations for multiple sclerosis patients. <em>Frontiers in Neurology</em>. https://doi.org/10.3389/fneur.2023.1197212
Vancouver
Macaron G, Larochelle C, Arbour N, Galmard M, Girard M, Prat A, et al. Impact of aging on treatment considerations for multiple sclerosis patients. Frontiers in Neurology. 2023. doi:10.3389/fneur.2023.1197212.
BibTeX
@article{gabrielle2023Impact,
title = {Impact of aging on treatment considerations for multiple sclerosis patients},
author = {Gabrielle Macaron and Catherine Larochelle and Nathalie Arbour and Manon Galmard and Marc Girard and Alexandre Prat and Pierre Duquette},
journal = {Frontiers in Neurology},
year = {2023},
doi = {10.3389/fneur.2023.1197212},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Medicine 2018
Open access · CC-BY
Scoping Review of Neuroimaging Studies Investigating Frailty and Frailty Components
Acibadem University 2021
Open access · US-GOV
Prevelance of Frailty and Its Associated Factors in Patients With Axial Spondyloarthritis
Dokuz Eylul University 2023
Open access · US-GOV
Evaluation of Sarcopenia and Associated Factors in Patients With Lipedema
The Journals of Gerontology Series A 2016
Open access · CC0
Moving Geroscience Into Uncharted Waters: Table 1.
Veterinary Pathology 2015
Citation only
Renal Pathology in a Nontraditional Aging Model: The Naked Mole-Rat ( Heterocephalus glaber )
Centro di Riferimento Oncologico - Aviano 2010
Open access · US-GOV